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INTRODUCTION
The importance of overall treatment time on the 
efficacy of radiotherapy for cancers, including head 
and neck cancers, is now well recognised. Over the last 
two decades cumulative evidence has demonstrated 
that prolongation of overall treatment time, whether 
due to delay or interruption of radiotherapy, is 
associated with lower survival and locoregional 
control rates (1- 4). 
 The biological effects of treatment interruptions 
(planned or unplanned), on clinical outcome has been 
attributed to accelerated tumour stem cell repopulation. 
Unlike other tumour cells, which have limited life span, 
tumour stem cells reproduce indefinitely and can 
therefore cause recurrence (4). Approximately 2 - 4 
weeks after the initiation of radiotherapy, surviving 
tumour stem cells repopulation in head and neck 
cancers accelerates and occurs continuously during 
radiation (3,4). Furthermore, where radiotherapy 
is interrupted by surgery the accelerated tumour 
repopulation may be triggered by the enhanced growth 
environment provided by the healing process (1). 
 The accelerated repopulation is a tumour response 
to radiation induced tumour cell death in which the cell 
cycle of the surviving stem cells is markedly increased 
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ABSTRACT
Objective: To determine the incidence of treatment interruption among head and neck 
cancer patients undergoing radical radiotherapy. 
Design: Prospective study
Setting: Kenyatta National Hospital (KNH), Nairobi. 
Subjects: Twenty six (M=16, F=10) patients undergoing radiotherapy for head and neck 
cancer between March and June 2006.
Main outcome measures: Frequency of radiation morbidities and treatment interuptions.
Results: There were 26 patients consisting of 16 males and 10 females aged  between 
21 and 70 years (mean = 49.6 years). Among these patients 12 (46.2%) had tumours in 
the oral cavity, six (23.1%) had nasopharyngeal tumours, two (7.7%) had pharyngeal 
tumours, and six (23.1%) had laryngeal tumours. All tumours were primary carcinomas 
except two pharyngeal tumours which were metastatic. Among the 26 patients, 13(50%) 
completed the course of radiotherapy within the prescribed duration while another 
13(50%) had treatment interruption. Of the 13 patients who had treatment interruption, 
one patient had a treatment gap of four days, seven patients had treatment gaps ranging 
between six and ten days, and five patients had treatment gaps of over ten days. The 
duration of treatment gaps ranged between four and 30 days. At the time of treatment 
interruption the cumulative radiation dose ranged from 22 to 58 Grey with a mean of 
38 Grey (Mode = 44 Grey). The most common side effect was xerostomia (92%). This 
was closely followed  by mucositis (88.5%), skin reactions (88.5%) dysphagia (84.5%) 
pain and suffering (76.9%). Loss of taste (61.5%), trismus (34.6%) and voice change 
(30.89%) were relatively less common. 
Conclusion: Our findings show that the probability of cancer control and cure among 
head and neck cancer patients treated at KNH could be severely eroded by treatment 
interruptions as a result of severe radiation morbidity. 
536 EAST AFRICAN MEDICAL JOURNAL December 2009 
during the times of radiation breaks. During accelerated 
repopulation the estimated tumour stem cell doubling 
time may shorten from approximately 60 days to 
four days (4). The molecular mechanisms underlying 
accelerated repopulation by tumour cells receiving sub-
lethal doses of radiotherapy likely involves pre-existing 
signal transduction pathway that have the potential to 
stimulate cellular proliferation (5). 
 In light of this evidence, several institutions have 
reviewed their treatment practices with the view to 
minimising treatment interruptions or providing dose 
compensation when the interruptions do occur. Where 
the interruptions are planned as part of the treatment 
regime such dose compensation is less complicated. 
The challenge is in managing unplanned treatment 
interruptions. 
 At the moment there is no data on the frequency 
and causes of interruptions of prescribed course of 
radiotherapy at KNH. Such knowledge is necessary 
to determine the need for changes in treatment 
practice in order to improve clinical outcome. The 
purpose of this study, therefore, was to determine 
the frequencies of treatment interruptions and the 
associated radiation morbidities among head and 
neck cancer patients undergoing radical radiotherapy 
at Kenyatta National Hospital. 
MATERIALS AND METHODS
Between March and June 2006 patients undergoing 
radiotherapy for head and neck cancer were evaluated 
for frequency of radiation morbidity and treatment 
interruptions through interviews, review of clinical 
notes and selected items of the McMaster University 
Head and Neck Radiotherapy Questionnaire (HNRQ-
QOL) translated into Kiswahili. The patients were 
seen every two weeks at the radiotherapy unit and 
only those patients whose treatments were completed 
within the study period were considered for analysis. 
Using a standardised schedule the following 
demographic and clinical data were collected and 
analysed; age, gender, site of the tumour, type 
and incidence of radiation morbidity, number and 
duration of treatment interruptions and cumulative 
radiation dose at the time of treatment interruption. 
The data were summarised by calculating their means, 
percentages and ranges. 
 The study was approved by the KNH and 
University of Nairobi Ethics, Research and Standards 
Committee. 
RESULTS
Patient, tumour and treatment profiles: Patient, tumour, 
treatment and morbidity profiles are shown in 
Table 1. There were 26 patients, comprising of 16 
males and 10 females with ages ranging from 21 to 70 
years (M = 49.6 years). Most of the tumours occurred 
in the oral cavity (46.2%) and the rest occurred in 
the nasopharynx and larynx. All tumours seen were 
squamous cell carcinoma. 
Table 1
Patient, tumour, radiation morbidity and treatment 
profiles
Parameter  No. (%)   
Age
   Range    21 - 70 
   Mean      49.6     
Gender 
   Male 16 62.0   
   Female 10  38.0   
Tumour site         
   Oral cavity 12 46.2   
   Nasopharynx 6  23.1   
   Pharynx 2 7.7   
   Larynx 6  23.1   
Tumour type 26 100   
    Carcinoma
Radiation morbidity         
   Xerostomia  92   
   Mucositis   88.5   
   Skin reaction  88.5   
   Odynophagia (Pain on swallowing)  84.5
   Pain and suffering  76.9   
   Loss of taste  61.5   
   Trismus  34.6   
   Voice change  30.89   
Treatment interruptions         
   Yes 13 50   
   No 13 50   
Treatment gaps
   Range      4 - 30 
   < 5 days 1 7.7   
   6 -10 days 7 53.8   
   > 10 days 5 38.5 
 Of the 26 patients, 13 (50%) completed treatment 
within the prescribed duration while another 13 
(50%) had treatment interruptions. Of the 13 patients 
whose treatments were interrupted, one had a rest 
period of four days, seven had rest periods ranging 
between six and ten days and five had over ten rest 
days. The rest days ranged from four to 30 days. At 
the time of treatment interruption the cumulative 
radiation dose ranged from 22 to 58 Grey with a 
mean of 38 Grey (Mode = 44 Grey). 
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Radiation morbidity: The frequency of radiation 
morbidity experienced by our patients is shown in 
Table 1. Xerostomia was the most common side effect 
followed by mucositis. Voice change was the least 
common side effect. 
DISCUSSION
The results of this study show a high incidence of 
treatment interruption however, neither the rate 
of interruption, nor the frequencies of treatment 
morbidity are uncommon (6, 7). A study carried out 
by the Scottish Radiological Society on patients with 
laryngeal tumour receiving radical radiotherapy 
found that only 34% of the patients were treated within 
the prescribed time while 66% had their treatment 
interrupted (7). This rate of treatment interruption is 
supported by other studies which show that more than 
30% of radical treatments of head and neck cancers 
are interrupted for various reasons (8-16). Of most 
concern, however, are the duration and timing of the 
treatment break. The minimum length of interruption 
which results in a significant effect on local tumour 
control is yet to be determined. However, data from 
split-course therapy studies show that a 14 - 16 day 
interruption definitely affects treatment outcome (17). 
Using mathematical models it has been estimated that 
an unscheduled interruption of one day can result in 
an absolute reduction of local control of some 1.4% 
while an unscheduled interruption of one week can 
result in a relative loss of local control ranging from 2% 
to 25% (Median = 14%) for (18 - 20). This corresponds 
to a median loss of 26% in two weeks (5 - 42%). It has 
been reported that prolongation of a 28-day course 
by three days or more seriously prejudices both the 
probability of local tumour control and survival 
unless the radiation dose is adequately increased 
(21). Considering these statistics, our findings of 
treatment interruptions ranging from 4 to 30 days is 
a major source of concern. 
 Besides duration, the timing of the treatment 
interruptions has been reported by some but not others 
as a crucial factor in determining the chances of cure 
in squamous cell carcinoma (8,9,22). Skladowski et al. 
(8) found that gaps at the beginning and the end of 
the schedule were potentially more harmful than gaps 
in the middle of the schedule (8,9,22). Harman et al. 
(9) found that gaps in the second half of the schedule 
were more harmful than gaps at the beginning of the 
schedule, supporting the hypothesis that the tumour 
clonogen repopulation accelerated towards the end 
of radiotherapy of squamous cell cancer. Robertson 
et al. (22) on the other hand found no evidence that 
gaps at the beginning or end of the schedule were 
potentially more harmful than those in the middle 
of the schedule. They thus concluded that a gap is 
a serious adverse event on a radiotherapy schedule 
irrespective of its position. However, it is not just the 
length of the unscheduled gap itself which should 
be cause for concern but also its effect on the overall 
treatment duration. For example an unscheduled 
a one-day treatment interruption that falls on the 
weekend can extend the treatment duration by three 
days, thus compounding the negative effects of the 
treatment interruption (22). In this study the timing 
of treatment interruption in relation to weekends and 
public holidays was not considered. Consequently 
the actual prolongation of treatment duration could 
be higher than estimated here. 
 There are myriad causes of unscheduled 
treatment interruptions, including radiation 
morbidity, financial difficulties, difficulties with 
transport, and machine breakdown. However, the 
most important of these is radiation morbidity. 
A treatment regime that results in frequent and/or 
severe tissue reactions adversely affects compliance 
as more patients are likely to require prolonged rest 
days (6). In an earlier study it was found that patients 
attending radiotherapy for head and neck tumours 
at the KNH radiotherapy unit suffered frequent and 
severe radiation morbidity (23). This may explain, at 
least in part, the frequent and prolonged duration of 
treatment interruptions in this study. It is, therefore, 
prudent to review current radiotherapy regimes at 
the unit in light of these findings. 
In conclusion, our findings show a high frequency 
and prolonged duration of treatment interruptions 
among head and neck cancer patients undergoing 
curative radiotherapy at KNH. However, there is 
no evidence of compensation for these treatment 
interruptions. Therefore, the probability of cancer 
control and cure among head and neck cancer patients 
treated at KNH could be severely eroded by the 
treatment interruptions 
 We hope that these results will lead to a review 
of radiotherapy practice at the KNH with the aim of 
reducing the frequency and severity of side effects 
and improving treatment compliance. 
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